Insights

Why Sorrento Therapeutics Stock Shot 7% Higher Today

What happened
A rising stock price is the cure for any investor’s glum mood. Sorrento Therapeutics (NASDAQ: SRNE) provided a big dose of this on Monday; its shares gained over 7% thanks to encouraging news from the laboratory about the company’s coronavirus drug candidate.
So what
That morning, Sorrento reported that it has reached full enrollment for its phase 1 study of that drug, Covishield. All told, 24 healthy recipients will be administered the drug, in the form of a nasal spray.
Image source: Getty Images.

As a nasally administered medicine, Covishield has a short pathway to upper airways and the lungs; COVID infections in these regions have been particularly damaging to many patients and have led to significant fatalities.
Sorrento added that Covishield’s safety profile is close to that of Covidrops, a similar treatment that has advanced into phase 2 testing. The biotech company’s findings indicate that Covidrops have had “only transient events” that were mild in severity and did not require treatment.
In its press release trumpeting the news, Sorrento quoted its chief medical officer, Mike Royal, as saying, “We are encouraged by the speed with which this study enrolled, as the IND was just cleared two months ago.” He was referring to the Food and Drug Administration’s Investigational New Drug (IND) designation. This essentially allows a biotech to quickly bring a pipeline drug to a clinical trial. 
Now what
Highly efficacious COVID vaccines have been on the market for quite some time and have made their way into a great many arms. But while a handful of treatments targeting the illness have been authorized around the world, there remains great opportunity for a particularly well-performing one to succeed widely. Sorrento investors’ hopes have been raised for Covishield to eventually be that drug.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

A rising stock price is the cure for any investor’s glum mood. Sorrento Therapeutics (NASDAQ: SRNE) provided a big dose of this on Monday; its shares gained over 7% thanks to encouraging news from the laboratory about the company’s coronavirus drug candidate.

So what

That morning, Sorrento reported that it has reached full enrollment for its phase 1 study of that drug, Covishield. All told, 24 healthy recipients will be administered the drug, in the form of a nasal spray.

Image source: Getty Images.

As a nasally administered medicine, Covishield has a short pathway to upper airways and the lungs; COVID infections in these regions have been particularly damaging to many patients and have led to significant fatalities.

Sorrento added that Covishield’s safety profile is close to that of Covidrops, a similar treatment that has advanced into phase 2 testing. The biotech company’s findings indicate that Covidrops have had “only transient events” that were mild in severity and did not require treatment.

In its press release trumpeting the news, Sorrento quoted its chief medical officer, Mike Royal, as saying, “We are encouraged by the speed with which this study enrolled, as the IND was just cleared two months ago.” He was referring to the Food and Drug Administration’s Investigational New Drug (IND) designation. This essentially allows a biotech to quickly bring a pipeline drug to a clinical trial. 

Now what

Highly efficacious COVID vaccines have been on the market for quite some time and have made their way into a great many arms. But while a handful of treatments targeting the illness have been authorized around the world, there remains great opportunity for a particularly well-performing one to succeed widely. Sorrento investors’ hopes have been raised for Covishield to eventually be that drug.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!